Pluribus Labs’s Bristol-Myers Squibb BMY Stock Holding History

Pluribus Labs’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$480K	Buy	+6,228	New	+$474K	0.88%	31

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pluribus Labs's BMY Position: Q2 2022 in Review

Pluribus Labs opened a new position in Bristol-Myers Squibb (BMY) in Q2 2022: 6,228 shares worth $480K. The stake represents 0.88% of the portfolio and ranks #31 among its holdings.

2,537 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Pluribus Labs held 6,228 shares of Bristol-Myers Squibb worth $480K as of Q2 2022.
Bristol-Myers Squibb was a new Pluribus Labs position in Q2 2022.
Bristol-Myers Squibb made up 0.88% of Pluribus Labs's portfolio in Q2 2022, its #31 holding.
2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.